Filing Flows › BioMarin Pharmaceutical (BMRN) › Q1 2026
BioMarin Pharmaceutical (BMRN) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 5, 2026
BioMarin Pharmaceutical (BMRN) reported revenue of $766M for the first quarter 2026 (Q1 2026), +3% from a year earlier and -12% from the quarter before. Operating margin was 16.9%, net earnings $106M (13.8% of revenue).
BioMarin Pharmaceutical, Q1 2026: revenue $766M (+3% year over year), operating margin 16.9%, net earnings $106M, operating cash flow $221M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $766M | -12% | +3% |
| Operating profit | $130M | — | -42% |
| Net earnings | $106M | — | -43% |
| Operating cash flow | $221M | +121% | +27% |
| Free cash flow | $200M | +239% | +27% |
What changed
Revenue was $766.2M in Q1 2026, up 3% year over year and down 12% from the previous quarter. VOXZOGO was the largest line at 29% of revenue. VIMIZIM added $21.9M year over year (up 12%), 104% of the total change. ROCTAVIAN declined 75%.
Operating profit was $129.6M, a 16.9% margin (down 13.1 points year over year). Operating profit fell $94.3M even though revenue rose $21.1M versus Q1 2025, so costs grew faster than sales. Total costs grew 22% against revenue growth of 3%. The fastest-growing cost line was Cost of revenue (+29%). Net earnings were $105.5M, down 43% year over year. The effective tax rate was 25.3%.
Operating cash flow was $220.7M (up 27% year over year), 209% of net earnings. Non-cash charges added back $16.4M of depreciation and amortization and $43.5M of share-based compensation. Working capital and other items added $55.3M. Capital expenditures of $20.9M left free cash flow of $199.7M.
Questions
What was BioMarin Pharmaceutical's revenue in the first quarter 2026?
BioMarin Pharmaceutical (BMRN) reported revenue of $766M for the first quarter 2026 (Q1 2026), +3% from a year earlier and -12% from the quarter before.
Was BioMarin Pharmaceutical profitable in the first quarter 2026?
Operating profit was $130M (16.9% of revenue) and net earnings $106M.